Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

NCT01509742 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of the medication liraglutide on glucagon levels in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 19 people

Who can join Ages 30–75 · all sexes

Timeline Started 2001-04 · est. completion 2001-11

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT01509742 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to examine the effect of NNC 90-1170 on the hypoglycaemic counterregulation in subjects with type 2 diabetes.

Treatments tested

liraglutide also known as NNC 90-1170 Drug

Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
placebo Drug

Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement

Main thing measured	Area under the Curve (AUC) glucagon
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01509742 ↗